Q-omics provides the consensus-scored TRIM66 profile across patient tissues and cancer cell-line models. TRIM66 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRIM66 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, TRIM66 RNA expression shows 20,438 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, THCA, and UVM as cancer lineages where TRIM66 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM66 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM66 survival associations across molecular data types. TRIM66 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM66 RNA expression–survival associations across cancer types. High TRIM66 expression shows unfavorable associations in ACC and KIRC, but favorable associations in HNSC, READ, SKCM and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRIM66 RNA expression.
This table summarizes TRIM66 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM66. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM66 shows lower tumor expression in THCA, KICH and BRCA and higher tumor expression in LIHC, COAD and STAD. The THCA box plot shows higher TRIM66 RNA expression in normal versus tumor tissue (log2 FC = −0.873, t-test p < 0.001).
This table shows molecular features associated with TRIM66 in patient tissues and cancer cell lines. In patient samples, TRIM66 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM66 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
